^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Melanoma
    Drug:ONCOS-102 (GM-CSF agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Targovax Press Release
    Title:

    FDA Grants Fast Track Designation to ONCOS-102 for Treatment of Advanced Melanoma

    Published date:
    06/22/2021
    Excerpt:
    ...Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast Track designation in PD-1-refractory advanced melanoma from the US FDA.